Summary of the webcast held on January 28, 2025
29/01/2025 – AB Science provides a summary of the webcast held on January 28, 2025
AB Science webcast of January 28, 2025
28/01/2025 – Presentation of the AB Science webcast held on January 28, 2025
Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
24/01/2025 – AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
AB Science will participate in the Biomed Forum investors conference
22/01/2025 – AB Science announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors, that will take place on February 4, 2025, in Paris
Summary of the webcast held on December 16, 2024
17/12/2024 – AB Science provides a summary of the webcast held on December 16, 2024
AB Science webcast of December 16, 2024
16/12/2024 – Presentation of the AB Science webcast held on December 16, 2024
Live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
11/12/2024 – AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
28/10/2024 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with masitinib
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis
Revenues for the first half of 2024 and update on AB Science’s activities
10/10/2024 – AB Science today reports its revenues for the first half of 2024 and provides an update on its activities